MAPT and Alzheimer disease: As expected, CSF p-tau 181 was higher in AD patients (n = 111) compared to ALS patients (n = 152) and disease controls (n = 99, both p < 0.001), with no difference between ALS and disease controls in the overall cohort as well as in the individual cohorts (Table 1, Supplementary Tables 2–5).